





AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Original) A compound of the formula



wherein A is of the formula



X and Y are each independently hydrogen, fluoro, chloro, bromo, or (C₁-C₆)alkyl;

R¹ is (C₂-C₆)alkyl, (C₃-C₆)alkenyl, or optionally substituted benzyl; wherein said benzyl may be optionally substituted with one to three substituents independently selected from HO-, (C₁-C₆)alkyl-O-, halo and amino;

R² is (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₃-C₆)alkynyl, (C₃-C₁₀)cycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heterocycll, (C₁-C₉)heteroaryl, (C₆-C₁₀)aryl(C₁-C₄)alkyl, (C₁-C₉)heterocycll-(C₁-C₄)alkyl, (C₁-C₉)heteroaryl-(C₁-C₄)alkyl, or (C₃-C₁₀)cycloalkyl-(C₁-C₄)alkyl; wherein each of the aforesaid groups may optionally be substituted with one to three substituents independently selected from halo, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, or -CF₃;

R³ is hydrogen, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₁₀)cycloalkyl, (C₁-C₉)heterocycll, (C₁-C₉)heteroaryl, or (C₆-C₁₀)aryl; wherein each of the aforesaid groups may be optionally substituted with one to three substituents independently selected from HO-, (C₁-C₆)alkyl-O-, halo and amino;

R⁴ is HO- or R¹⁴R¹⁵N-;

R^5 is a radical selected from the group consisting of hydrogen, halo, (C_1 - C_6)alkyl, (C_2 - C_6)alkenyl, (C_3 - C_6)alkynyl, (C_3 - C_{10})cycloalkyl, (C_6 - C_{10})aryl-, (C_1 - C_9)heteroaryl-, (C_1 - C_9)heterocyclic-, -OH, (C_1 - C_6)alkyl-O-, (C_3 - C_{10})cycloalkyl-O-, (C_6 - C_{10})aryl-O-, (C_1 - C_9)heteroaryl-O-, (C_1 - C_9)heterocyclic-O-, (C_3 - C_{10})cycloalkyl-(C_1 - C_6)alkyl-O-, (C_6 - C_{10})aryl-(C_1 - C_6)alkyl-O-, (C_1 - C_9)heteroaryl-(C_1 - C_6)alkyl-O-, (C_1 - C_9)heterocyclic-(C_1 - C_6)alkyl-O-, $R^{16}R^{17}N$ -(C=O)-, R^{16} -(C=O)-(R²⁵-N)-, $R^{16}R^{17}N$ -(C=O)-O-, R¹⁸-SO₂-, R¹⁸-SO₂-(NR¹⁹)-, R¹⁸-SO₃-, -C≡N, R¹⁸-(C=O)-O-, R¹⁸-(C=O)-, R¹⁶R¹⁷N-(C=O)-O-, R¹⁶R¹⁷N-(C=O)-(R²⁵-N)-, R¹⁹-O-(C=O)-(R²⁵-N)-, and R¹⁹-O-(C=O)-; wherein each of said (C_1 - C_6)alkyl, (C_3 - C_{10})cycloalkyl, (C_6 - C_{10})aryl, (C_1 - C_9)heteroaryl, (C_1 - C_9)heterocyclic moieties of said (C_1 - C_6)alkyl, (C_6 - C_{10})aryl-, (C_1 - C_9)heteroaryl-, (C_1 - C_9)heterocyclic-, (C_1 - C_6)alkyl-O-, (C_3 - C_{10})cycloalkyl-O-, (C_6 - C_{10})aryl-O-, (C_1 - C_9)heteroaryl-O-, (C_1 - C_9)heterocyclic-O-, (C_3 - C_{10})cycloalkyl-(C_1 - C_6)alkyl-O-, (C_6 - C_{10})aryl-(C_1 - C_6)alkyl-O-, (C_1 - C_9)heteroaryl-(C_1 - C_6)alkyl-O- and (C_1 - C_9)heterocyclic-(C_1 - C_6)alkyl-O- radicals, may optionally be substituted with one to three substituents independently selected from the group consisting of (C_1 - C_6)alkyl, (C_2 - C_6)alkenyl, (C_2 - C_6)alkynyl, (C_3 - C_{10})cycloalkyl, (C_6 - C_{10})aryl, (C_1 - C_9)heteroaryl(CH₂)_n-, (C_1 - C_9)heterocyclic, halo, HO-, HO-(C=O)-, R²⁰-O-(C=O)-, R²¹-(C=O)-, R²²-CO₂-, N≡C-, R²³R²⁴N-, R²³R²⁴N-(C_1 - C_6)alkyl-, R²³R²⁴N-(C=O)-, R²³R²⁴N-SO₂-, R²¹-SO₂-, R²¹-SO₂-(NR²¹)-, R²¹-SO₃-, R²¹(C=O)-NH-, R²¹(C=O)-[N-(C_1 - C_6)alkyl]-; R²¹(C=O)-NH-(C_1 - C_6)alkyl-; and R²¹(C=O)-[N-(C_1 - C_6)alkyl]-(C_1 - C_6)alkyl-; wherein said (C_3 - C_{10})cycloalkyl, (C_6 - C_{10})aryl, (C_1 - C_9)heteroaryl(CH₂)_n-, (C_1 - C_9)heterocyclic substituents may optionally be substituted on a ring carbon or nitrogen by one to three members per ring independently selected from halo, (C_1 - C_6)alkyl, and (C_1 - C_6)alkoxy;

n is an integer from zero to four;

each of R^6 , R^7 , R^8 and R^9 is independently selected from the group consisting of hydrogen, (C_1 - C_6)alkyl, fluoro and -OH;

each of R^{10} and R^{11} is independently selected from the group consisting of hydrogen and (C_1 - C_6)alkyl;

each of R^{12} and R^{13} is independently selected from the group consisting of hydrogen, fluoro and (C_1 - C_6)alkyl;

each of R^{14} and R^{15} is independently selected from hydrogen or (C_1 - C_4)alkyl;


each of R¹⁶ and R¹⁷ is independently selected from hydrogen, (C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₉)heterocyclic, (C₁-C₉)heteroaryl(C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₁-C₉)heterocyclic(C₁-C₆)alkyl, HO-(C₁-C₆)alkyl, amino-(C₁-C₆)alkyl-, (C₁-C₆)alkylamino-(C₁-C₆)alkyl-, and [(C₁-C₆)alkyl]₂amino-(C₁-C₆)alkyl-; wherein said each of said (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, and (C₁-C₉)heterocyclic moieties of said (C₆-C₁₀)aryl-, (C₁-C₉)heteroaryl-, (C₁-C₉)heterocyclic-, (C₆-C₁₀)aryl-(C₁-C₆)alkyl, (C₁-C₉)heteroaryl-(C₁-C₆)alkyl and (C₁-C₉)heterocyclic-(C₁-C₆)alkyl, may optionally be substituted with one to three substituents independently selected from the group consisting of halo, (C₁-C₆)alkyl or (C₁-C₆)alkoxy, or R¹⁶ and R¹⁷ are taken together to form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, (C₁-C₆)alkyl-piperazinyl, or morpholinyl ring; R¹⁸ is hydrogen, (C₁-C₆)alkyl, (C₆-C₁₀)aryl or (C₁-C₉)heteroaryl; wherein said (C₁-C₆)alkyl may optionally be substituted with a substituent selected from the group consisting of HO-, amino, (C₁-C₆)alkylamino, [(C₁-C₆)alkyl]₂amino, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₉)heterocyclic, (C₁-C₆)alkoxy, HO-(C=O)-, (C₁-C₆)alkyl-O-(C=O)-, (C₁-C₆)alkyl-(C=O)-, N≡C-, [(C₁-C₆)alkyl]₂N-(C=O)- and (C₁-C₆)alkyl(C=O)-NH-; R¹⁹ is hydrogen or (C₁-C₆)alkyl; R²⁰ is hydrogen or (C₁-C₆)alkyl; R²¹ is hydrogen or (C₁-C₆)alkyl; R²² is hydrogen or (C₁-C₆)alkyl; each of R²³ and R²⁴ is independently selected from hydrogen, (C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₉)heterocyclic, (C₁-C₉)heteroaryl(C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₁-C₉)heterocyclic(C₁-C₆)alkyl, HO-(C₁-C₆)alkyl, N≡C-(C₁-C₆)alkyl, amino-(C₁-C₆)alkyl-, (C₁-C₆)alkylamino-(C₁-C₆)alkyl-, and [(C₁-C₆)alkyl]₂amino-(C₁-C₆)alkyl-; wherein said each of said (C₆-C₁₀)aryl-, (C₁-C₉)heteroaryl, and (C₁-C₉)heterocyclic moieties of said (C₆-C₁₀)aryl-, (C₁-C₉)heteroaryl-, (C₁-C₉)heterocyclic-, (C₆-C₁₀)aryl-(C₁-C₆)alkyl, (C₁-C₉)heteroaryl-(C₁-C₆)alkyl and (C₁-C₉)heterocyclic-(C₁-C₆)alkyl, may optionally be substituted with one to three substituents independently selected from the group consisting of halo, (C₁-C₆)alkyl or (C₁-C₆)alkoxy, or R²³ and R²⁴ are taken together to

form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, (C₁-C₆)alkyl-piperazinyl, or morpholinyl ring;


R²⁵ is hydrogen or (C₁-C₆)alkyl;

or a pharmaceutically acceptable salt thereof.


2. (Currently Amended) A compound according to claim 1, wherein said compound has the formula



3. (Currently Amended) A compound according to claim 1, wherein said compound has the formula




4. (Original) A compound according to claim 1, wherein said compound has the formula




1a

5. (Currently Amended) A compound according to claim 1, wherein said compound has the formula




6. (Currently Amended) compound has the formula

A compound according to claim 1, wherein said




7. (Currently Amended) compound has the formula

A compound according to claim 1, wherein said



8. (Withdrawn) has the formula


A compound according to claim 1, wherein said compound




1b

9. (Withdrawn-Currently Amended) wherein said compound has the formula


A compound according to claim 1,




10. (Withdrawn-Currently Amended) A compound according to claim 1, wherein said compound has the formula



11. (Withdrawn-Currently Amended) A compound according to claim 1, wherein said compound has the formula




12. (Original) A compound according to claim 1, wherein said compound has the formula




1c


13. (Withdrawn-Currently Amended) A compound according to claim 1, wherein said compound has the formula



14. (Withdrawn-Currently Amended) A compound according to claim 1, wherein said compound has the formula



15. (Withdrawn-Currently Amended) A compound according to claim 1, wherein said compound has the formula



16. (Currently Amended) A compound according to claim 1 ~~any of the foregoing claims~~, wherein R¹ is ethyl or allyl.

17. (Currently Amended) A compound according to claim 1 ~~any of the foregoing claims~~, wherein R² is optionally substituted (C₆-C₁₀)aryl.

18. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is optionally substituted (C₁-C₉)heteroaryl.

19. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is optionally substituted (C₃-C₅)heteroaryl.

20. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is optionally substituted (C₁-C₉)heterocyclyl.

21. (Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is optionally substituted phenyl.

22. (Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is phenyl.

23. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is optionally substituted thiazolyl.

24. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is optionally substituted pyridyl.

25. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is optionally substituted oxazolyl.

26. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is optionally substituted pyridin-2-yl.

27. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is optionally substituted thiazol-2-yl.

28. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is optionally substituted oxazol-2-yl.

29. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is pyridin-2-yl; optionally substituted with a substituent selected from halo, CF₃, and (C₁-C₆)alkyl.

30. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is thiazol-2-yl; optionally substituted with a substituent selected from halo, CF₃, or (C₁-C₆)alkyl.

31. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is oxazol-2-yl; optionally substituted with a substituent selected from halo, CF₃, or (C₁-C₆)alkyl.

32. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is pyridin-2-yl.

33. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is thiazol-2-yl.

34. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is oxazol-2-yl.

35. (Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is (C₃-C₆)alkynyl.

36. (Currently Amended) A compound according to claim 1 ~~claims 1-16~~, wherein R² is (C₂-C₆)alkenyl.

37. (Currently Amended) A compound according to claim 1 ~~any of the foregoing claims~~, wherein R³ is hydrogen.

38. (Currently Amended) A compound according to claim 1 ~~claims 1-36~~, wherein R³ is (C₁-C₆)alkyl optionally substituted with a substituent selected from halo or hydroxy.

39. (Currently Amended) A compound according to claim 1 ~~claims 1-36~~, wherein R³ is methyl, ethyl or propyl.

40. (Currently Amended) A compound according to claim 1 ~~claims 1-36~~, wherein R³ is methyl.

41. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-36~~, wherein R³ is optionally substituted (C₁-C₉)heteroaryl.

42. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-36~~, wherein R³ is optionally substituted (C₁-C₉)heterocyclyl.

43. (Currently Amended) A compound according to claim 1 ~~claims 1-36~~, wherein R³ is optionally substituted (C₆-C₁₀)aryl.

44. (Currently Amended) A compound according to claims 1, 4, 5, 6, and 7 ~~any of the foregoing claims~~, wherein R⁴ is HO-.

45. (Currently Amended) A compound according to claim 1 ~~claims 1-36~~, wherein R⁴ is R¹⁴R¹⁵N-.

46. (Withdrawn-Currently Amended) A compound according to claim 1 ~~any of the foregoing claims~~, wherein R⁵ is -OH.

47. (Currently Amended) A compound according to claim 1 ~~claims 1-45~~, wherein R⁵ is (C₁-C₆)alkyl-O-, (C₃-C₁₀)cycloalkyl-O-, (C₆-C₁₀)aryl-O-, (C₁-C₉)heteroaryl-O-, or (C₁-C₉)heterocyclic-O-, wherein each of said (C₁-C₆)alkyl, (C₃-C₁₀)cycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₉)heterocyclic moieties of said (C₁-C₆)alkyl-O-, (C₃-C₁₀)cycloalkyl-O-, (C₆-C₁₀)aryl-O-, (C₁-C₉)heteroaryl-O-, (C₁-C₉)heterocyclic-O- radicals may optionally be substituted with one to three substituents independently selected from (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₁₀)cycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₉)heterocyclic, halo, HO-, HO-(C=O)-, R²¹-(C=O)-, R²²-CO₂-, N≡C-, R²³R²⁴N-, R²³R²⁴N-(C=O)-, R²¹(C=O)-NH-, R²¹(C=O)-[N-(C₁-C₆)alkyl]-.

48. (Withdrawn-Currently Amended) A compound according to claim 1 ~~claims 1-45~~, wherein R⁵ is optionally substituted (C₆-C₁₀)aryl-, (C₁-C₉)heteroaryl-, (C₁-C₉)heterocyclic-, (C₆-C₁₀)aryl-(C₁-C₆)alkyl, (C₁-C₉)heteroaryl-(C₁-C₆)alkyl or (C₁-C₉)heterocyclic-(C₁-C₆)alkyl; optionally substituted with one to three substituents independently selected from (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₁₀)cycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₉)heterocyclic, halo, HO-, HO-(C=O)-, R²¹-(C=O)-, R²²-CO₂-, N≡C-, R²³R²⁴N-, R²³R²⁴N-(C=O)-, R²¹(C=O)-NH-, R²¹(C=O)-[N-(C₁-C₆)alkyl]-.

49. (Currently Amended) A compound according to claim 1 ~~claims 1-45~~, wherein R⁵ is (C₆-C₁₀)aryl-(C₁-C₆)alkyl-O-, (C₁-C₉)heteroaryl-(C₁-C₆)alkyl-O-, (C₁-C₉)heterocyclic-(C₁-C₆)alkyl-O-, wherein each of said (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₉)heterocyclic moieties of said (C₆-C₁₀)aryl-(C₁-C₆)alkyl-O-, (C₁-C₉)heteroaryl-(C₁-C₆)alkyl-O-, and (C₁-C₉)heterocyclic-(C₁-C₆)alkyl-O-, may optionally be substituted with one to three substituents independently selected from the group consisting of (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₁₀)cycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(CH₂)_n-, (C₁-C₉)heterocyclic, halo, HO-, HO-(C=O)-, R²⁰-O-(C=O)-, R²¹-(C=O)-, R²²-CO₂-, N≡C-, R²³R²⁴N-, R²³R²⁴N-(C₁-C₆)alkyl-, R²³R²⁴N-(C=O)-, R²¹(C=O)-NH-, R²¹(C=O)-[N-(C₁-C₆)alkyl]-; R²¹(C=O)-NH-(C₁-C₆)alkyl-; and R²¹(C=O)-[N-(C₁-C₆)alkyl]-(C₁-C₆)alkyl-; wherein said (C₃-C₁₀)cycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(CH₂)_n-, (C₁-C₉)heterocyclic substituents may optionally be substituted on a ring carbon or nitrogen by one to three members per ring independently selected from halo, (C₁-C₆)alkyl, and (C₁-C₆)alkoxy.

50. (Currently Amended) A compound according to claim 1 ~~claims 1-45~~, wherein R⁵ is (C₆-C₁₀)aryl-(C₁-C₆)alkyl-O-, (C₁-C₉)heteroaryl-(C₁-C₆)alkyl-O-, (C₁-C₉)heterocyclic-(C₁-C₆)alkyl-O-, wherein each of said (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₉)heterocyclic moieties of said (C₆-C₁₀)aryl-(C₁-C₆)alkyl-O-, (C₁-C₉)heteroaryl-(C₁-C₆)alkyl-O-, and (C₁-C₉)heterocyclic-(C₁-C₆)alkyl-O-, may optionally be substituted with a substituent selected from the group consisting of

(C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₁₀)cycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(CH₂)_n-, (C₁-C₉)heterocyclic, halo, HO-, HO-(C=O)-, R²⁰-O-(C=O)-, R²¹-(C=O)-, R²²-CO₂-, N≡C-, R²³R²⁴N-, R²³R²⁴N-(C₁-C₆)alkyl-, R²³R²⁴N-(C=O)-, R²¹(C=O)-NH-, R²¹(C=O)-[N-(C₁-C₆)alkyl]-; R²¹(C=O)-NH-(C₁-C₆)alkyl-; and R²¹(C=O)-[N-(C₁-C₆)alkyl]-(C₁-C₆)alkyl-; wherein said (C₃-C₁₀)cycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(CH₂)_n-, (C₁-C₉)heterocyclic substituents may optionally be substituted on a ring carbon or nitrogen by one to three members per ring independently selected from halo, (C₁-C₆)alkyl, and (C₁-C₆)alkoxy.

51. (Currently Amended) A compound according to claim 1 claims 1-45, wherein R⁵ is (C₁-C₉)heteroaryl-(C₁-C₆)alkyl-O- optionally substituted with one to two substituents independently selected from the group consisting of (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₁₀)cycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(CH₂)_n-, (C₁-C₉)heterocyclic, halo, HO-, HO-(C=O)-, R²⁰-O-(C=O)-, R²¹-(C=O)-, R²²-CO₂-, N≡C-, R²³R²⁴N-, R²³R²⁴N-(C₁-C₆)alkyl-, R²³R²⁴N-(C=O)-, R²¹(C=O)-NH-, R²¹(C=O)-[N-(C₁-C₆)alkyl]-; R²¹(C=O)-NH-(C₁-C₆)alkyl-; and R²¹(C=O)-[N-(C₁-C₆)alkyl]-(C₁-C₆)alkyl-; wherein said (C₃-C₁₀)cycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(CH₂)_n-, (C₁-C₉)heterocyclic substituents may optionally be substituted on a ring carbon or nitrogen by one to three members per ring independently selected from halo, (C₁-C₆)alkyl, and (C₁-C₆)alkoxy.

52. (Currently Amended) A compound according to claim 1 claims 1-45, wherein R⁵ is (C₁-C₉)heteroaryl-(C₁-C₆)alkyl-O- optionally substituted with one to two substituents independently selected from the group consisting of (C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(CH₂)_n-, halo, HO-, HO-(C=O)-, R²⁰-O-(C=O)-, R²¹-(C=O)-, R²²-CO₂-, N≡C-, R²³R²⁴N-, R²³R²⁴N-(C₁-C₆)alkyl-, R²³R²⁴N-(C=O)-, R²¹(C=O)-NH-, R²¹(C=O)-[N-(C₁-C₆)alkyl]-; R²¹(C=O)-NH-(C₁-C₆)alkyl-; and R²¹(C=O)-[N-(C₁-C₆)alkyl]-(C₁-C₆)alkyl-; wherein said (C₃-C₁₀)cycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(CH₂)_n-, (C₁-C₉)heterocyclic substituents may optionally be substituted on a ring carbon or nitrogen by one to two members per ring independently selected from halo, (C₁-C₆)alkyl, and (C₁-C₆)alkoxy;

wherein n is an integer from zero to two;
wherein each of R²³ and R²⁴ is independently selected from hydrogen, (C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₉)heterocyclic, (C₁-C₉)heteroaryl(C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₁-C₉)heterocyclic(C₁-C₆)alkyl, HO-(C₁-C₆)alkyl, amino-(C₁-C₆)alkyl-, (C₁-C₆)alkylamino-(C₁-C₆)alkyl-, and [(C₁-C₆)alkyl]₂amino-(C₁-C₆)alkyl-; wherein said each of said (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, and (C₁-C₉)heterocyclic moieties of said (C₆-C₁₀)aryl-, (C₁-C₉)heteroaryl-, (C₁-C₉)heterocyclic-, (C₆-C₁₀)aryl-(C₁-C₆)alkyl, (C₁-C₉)heteroaryl-(C₁-C₆)alkyl and (C₁-C₉)heterocyclic-(C₁-C₆)alkyl, may optionally be substituted with one to two substituents independently selected from the group consisting of halo, (C₁-C₆)alkyl or (C₁-C₆)alkoxy, or R²³ and R²⁴ are taken together to form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, (C₁-C₆)alkyl-piperazinyl or morpholinyl ring.

53. (Withdrawn-Currently Amended) A compound according to claim 1 claims 1-45, wherein R⁵ is optionally substituted (C₁-C₆)alkyl-O-.

54. (Withdrawn-Currently Amended) A compound according to claim 1 claims 1-45, wherein R⁵ is (C₁-C₆)alkyl-O- optionally substituted with one to three substituents independently selected from the group consisting of (C₃-C₁₀)cycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl and (C₁-C₉)heterocyclic; wherein said (C₃-C₁₀)cycloalkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl(CH₂)_n-, (C₁-C₉)heterocyclic substituents may optionally be substituted on a ring carbon or nitrogen by one to three members per ring independently selected from halo, (C₁-C₆)alkyl, and (C₁-C₆)alkoxy.

55. (Withdrawn-Currently Amended) A compound according to claim 1 claims 1-45, wherein R⁵ is (C₁-C₆)alkyl-O- substituted with one substituent selected from the group consisting of halo, HO-, HO-(C=O)-, R²⁰-O-(C=O)-, R²¹-(C=O)-, R²²-CO₂-, N≡C-, R²³R²⁴N-, R²³R²⁴N-(C=O)-, R²¹(C=O)-NH-, and R²¹(C=O)-[N-(C₁-C₆)alkyl]-; wherein R²³ and R²⁴ is independently selected from hydrogen, (C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, (C₁-C₉)heterocyclic, (C₁-C₉)heteroaryl(C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₁-C₉)heterocyclic(C₁-C₆)alkyl, HO-(C₁-C₆)alkyl,

N≡C-(C₁-C₆)alkyl, amino-(C₁-C₆)alkyl-, (C₁-C₆)alkylamino-(C₁-C₆)alkyl-, and [(C₁-C₆)alkyl]₂amino-(C₁-C₆)alkyl-; wherein said each of said (C₆-C₁₀)aryl, (C₁-C₉)heteroaryl, and (C₁-C₉)heterocyclic moieties of said (C₆-C₁₀)aryl-, (C₁-C₉)heteroaryl-, (C₁-C₉)heterocyclic-, (C₆-C₁₀)aryl-(C₁-C₆)alkyl, (C₁-C₉)heteroaryl-(C₁-C₆)alkyl and (C₁-C₉)heterocyclic-(C₁-C₆)alkyl, may optionally be substituted with one to two substituents independently selected from the group consisting of halo, (C₁-C₆)alkyl or (C₁-C₆)alkoxy, or R²³ and R²⁴ are taken together to form an azetidinyl, pyrrolidinyl, piperidinyl or morpholinyl ring.

56. (Withdrawn-Currently Amended) A compound according to claims 1, 4, 5, 6, and 7 ~~claims 1-45~~, wherein R⁵ is -C≡N, R¹⁶R¹⁷N-(C=O)-, R¹⁶R¹⁷-N-SO₂-, R¹⁸-SO₂-, R¹⁸-SO₂-(NR¹⁹)-, R¹⁸-SO₃-, R¹⁶-(C=O)-(R²⁵-N)-, R¹⁶R¹⁷N-(C=O)-(R²⁵-N)-, R¹⁹-O-(C=O)-(R²⁵-N)-, R¹⁸-(C=O)-O-, R¹⁸-(C=O)-, R¹⁶R¹⁷N-(C=O)-O- or R¹⁹-O-(C=O)-.

57. (Withdrawn-Currently Amended) A compound according to claims 1, 4, 5, 6, and 7 ~~claims 1-45~~, wherein R⁵ is R¹⁶R¹⁷N-(C=O)-.

58. (Currently Amended) A compound according to claim 1 ~~claims 1-57~~, wherein X and Y are each hydrogen.

59. (Currently Amended) A compound according to claim 1 ~~claims 1-57~~, wherein one of X and Y is fluoro, chloro, or bromo.

60. (Currently Amended) A compound according to claim 1 ~~claims 1-57~~, wherein each of X and Y are independently selected from hydrogen, fluoro, chloro, or bromo.

61. (Currently Amended) A compound according to claim 1 ~~claims 1-57~~, wherein one of X and Y is (C₁-C₆)alkyl.

62. (Original) A compound according to claim 1, wherein said compound is

(2*R*, 3*S*, 4*aR*, 10*aR*)-4*a*-Ethyl-2-prop-1-ynyl-1,2,3,4,4*a*,9,10,10*a*-octahydrophenanthrene-2,3,7-triol;

(2*R*, 3*S*, 4*aR*, 10*aR*)-4*a*-Ethyl-7-(2-methylpyridin-3-ylmethoxy)-2-prop-1-ynyl-1,2,3,4,4*a*,9,10,10*a*-octahydrophenanthrene-2,3-diol;

(2*R*, 3*R*, 4*aR*, 10*aR*)-7-[5-(2-Dimethylaminoethyl)-[1,2,4]oxadiazol-3-ylmethoxy]-4*a*-ethyl-3-methyl-2-phenyl-1,2,3,4,4*a*,9,10,10*a*-octahydrophenanthrene-2,3-diol

(2*R*, 3*R*, 4*aR*, 10*aR*)-4*a*-Ethyl-3-methyl-2-pyridin-2-yl-1,2,3,4,4*a*,9,10,10*a*-octahydrophenanthrene-2,3,7-triol;

(2*R*, 3*R*, 4*aR*, 10*aR*)-4*a*-Ethyl-3-methyl-7-(2-methylpyridin-3-ylmethoxy)-2-pyridin-2-yl-1,2,3,4,4*a*,9,10,10*a*-octahydrophenanthrene-2,3-diol;

(2*R*, 3*S*, 4*aR*, 10*aR*)-4*a*-Ethyl-3-methyl-2-thiazol-2-yl-1,2,3,4,4*a*,9,10,10*a*-octahydrophenanthrene-2,3,7-triol;

(2*R*, 3*S*, 4*aR*, 10*aR*)-4*a*-Ethyl-3-methyl-2-(4-methylthiazol-2-yl)-1,2,3,4,4*a*,9,10,10*a*-octahydrophenanthrene-2,3,7-triol;

(2*R*, 3*R*, 4*aR*, 10*aS*)-4*a*-Ethyl-2,3,7-trihydroxy-3-methyl-2-phenyl-2,3,4,4*a*,10,10*a*-hexahydro-1*H*-phenanthren-9-one;

(2*R*, 3*R*, 4*aR*, 10*aS*)-4*a*-Ethyl-3,9-dimethyl-2-phenyl-1,2,3,4,4*a*,10*a*-hexahydro-phenanthrene-2,3,7-triol;

(2*R*, 3*R*, 4*aR*, 10*aR*)-3,4*a*-Diethyl-2-phenyl-1,2,3,4,4*a*,9,10,10*a*-octahydro-phenanthrene-2,3,7-triol;

(2*R*, 3*R*, 4*aR*, 10*aR*)-4*a*-Ethyl-7-(2-hydroxy-ethoxy)-3-methyl-2-phenyl-1,2,3,4,4*a*,9,10,10*a*-octahydro-phenanthrene-2,3-diol;

(2*R*, 3*R*, 4*aR*, 10*aR*)-4*a*-Ethyl-7-(3-hydroxy-propoxy)-3-methyl-2-phenyl-1,2,3,4,4*a*,9,10,10*a*-octahydro-phenanthrene-2,3-diol;

(2*R*, 3*R*, 4*aR*, 10*aR*)-4*a*-Ethyl-7-(4-hydroxy-butoxy)-3-methyl-2-phenyl-1,2,3,4,4*a*,9,10,10*a*-octahydro-phenanthrene-2,3-diol;

(4*bR*, 7*R*, 6*R*, 8*aR*)-4-(4*b*-Ethyl-6,7-dihydroxy-6-methyl-7-phenyl-4*b*,5,6,7,8,8*a*,9,10-octahydro-phenanthren-2-yloxy)-butyronitrile;

(4*bR*, 7*R*, 6*R*, 8*aR*)-5-(4*b*-Ethyl-6,7-dihydroxy-6-methyl-7-phenyl-4*b*,5,6,7,8,8*a*,9,10-octahydro-phenanthren-2-yloxy)-pentanenitrile;

(4b*R*, 7*R*, 6*R*, 8*aR*)-2-(4b-Ethyl-6,7-dihydroxy-6-methyl-7-phenyl-4*b*,5,6,7,8,8*a*,9,10-octahydro-phenanthren-2-yloxy)-acetamide;

(2*R*, 3*R*, 4*aR*, 10*aR*)-4a-Ethyl-7-(4-hydroxy-4-methyl-pentyloxy)-3-methyl-2-phenyl-1,2,3,4,4*a*,9,10,10*a*-octahydro-phenanthrene-2,3-diol;

(2*R*, 3*R*, 4*aR*, 10*aR*)-4a-Ethyl-7-(5-hydroxy-5-methyl-hexyloxy)-3-methyl-2-phenyl-1,2,3,4,4*a*,9,10,10*a*-octahydro-phenanthrene-2,3-diol;

(2*R*, 3*R*, 4*aR*, 10*aR*)-4a-Ethyl-3-methyl-2-prop-1-ynyl-1,2,3,4,4*a*,9,10,10*a*-octahydro-phenanthrene-2,3,7-triol;

(2*R*, 3*R*, 4*aR*, 10*aR*)-4a-Ethyl-3-methyl-2-p-tolyl-1,2,3,4,4*a*,9,10,10*a*-octahydro-phenanthrene-2,3,7-triol; and

(2*R*, 3*R*, 4*aR*, 10*aR*)-4a-Ethyl-3-methyl-2-propenyl-1,2,3,4,4*a*,9,10,10*a*-octahydro-phenanthrene-2,3,7-triol.

63. (Withdrawn) A method of treating a disorder selected from the group consisting of inflammatory disorders, endocrine disorders; collagen diseases; dermatologic diseases; allergic states; ophthalmic diseases; respiratory diseases; hematologic disorders; neoplastic diseases; edematous states; and gastrointestinal diseases in a mammal comprising administering to said mammal a therapeutically effective amount of a compound according to claim 1.

64. (Original) A pharmaceutical composition for treating a disorder selected from the group consisting of inflammatory disorders, endocrine disorders; collagen diseases; dermatologic diseases; allergic states; ophthalmic diseases; respiratory diseases; hematologic disorders; neoplastic diseases; edematous states; and gastrointestinal diseases in a mammal comprising a therapeutically effective amount of a compound according to claim 1 or a salt or prodrug thereof, and a pharmaceutically acceptable carrier.

65. (Withdrawn) A method of treating inflammation in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of

claim 1, an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug.

66. (Original) A pharmaceutical composition for the treatment of inflammation comprising an amount of a compound of claim 1 effective for treating inflammation, an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug; and a pharmaceutically acceptable carrier, vehicle or diluent.

67. (New) A compound according to claims 1, 4, 5, 6, and 7, wherein

R⁴ is HO-; and

R⁵ is -C≡N, R¹⁶R¹⁷N-(C=O)-, R¹⁶R¹⁷-N-SO₂-, R¹⁸-SO₂-, R¹⁸-SO₂-(NR¹⁹)-, R¹⁸-SO₃-, R¹⁶-(C=O)-(R²⁵-N)-, R¹⁶R¹⁷N-(C=O)-(R²⁵-N)-, R¹⁹-O-(C=O)-(R²⁵-N)-, R¹⁸-(C=O)-O-, R¹⁸-(C=O)-, R¹⁶R¹⁷N-(C=O)-O- or R¹⁹-O-(C=O)-.